Key staff from PEGUS are pleased to participate in two upcoming public FDA advisory committee meetings for potential 1st in class OTC switch candidates we have supported with research:
- First in Class OTC Nasal Naloxone (Opioid Overdose Reversal): February 15, 2023: Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement – 02/15/2023 | FDA
- First in Class OTC Oral Contraceptive (Note this meeting was initially scheduled for Nov. 2022 but postponed to allow time for the FDA to review new information, and new dates for the meeting are expected soon): POSTPONED: November 18, 2022 Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement – 11/18/2022 | FDA
